Author: GSBS | Category: In The News | GSBS Alumni | Cell Biology, Genetics & Molecular Medicine (CGM) | April 12, 2017
Alum David Bearss is now the chief executive officer of Lehi-based biotech firm Tolero Pharmaceuticals, whose team of scientists is conducting clinical trials on a drug that has shown promise in treating acute myeloid leukemia, or AML. David Bearss is a PhD graduate of the Cellular & Structural Biology Graduate Program. He was in the lab of Jolene Windle and he graduated in 1999. He was also the CSB Graduate Program’s Distinguished Alumnus in 2012.
Photo Credit: Laura Seitz, Deseret news
Copyright © 2017 The University of Texas Health Science Center at San Antonio
Links provided from the UTHSCSA pages to other websites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.